## India Not Rated

Consensus ratings*:	Buy 2	Hold 1	Sell 0
Current price:			Rs104
Target price:			0
Previous target:			Rs300
Up/downside:			188.5%
InCred Research / Cor	nsensus	:	172.7%
Reuters:		С	AMF.BO
Bloomberg:			CFIN IN
Market cap:		ι	JS\$240m
		Rs	17,425m
Average daily turnover	r:	ι	JS\$1.8m
		R	s130.4m
Current shares o/s:			157.0m
Free float:			83.3%
*Source: Bloomberg			



# **Camlin Fine Sciences**

## Cessation of coverage

- Following a review of our research universe, we discontinue coverage of Camlin Fine Sciences due to reallocation of resources.
- As such, all our previous forecasts, valuations, and recommendations for Camlin Fine Sciences should no longer be relied upon for investment decisions.

Research	Anal	vst	S	)
11000ul oli	7.1101	,		,



Satish KUMAR T (91) 22 4161 1562 E satish.kumar@incredresearch.com Abbas PUNJANI T (91) 22 4161 1598 E abbas.punjani@incredresearch.com

Financial Summary	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
Revenue (Rsm)	11,871	14,121	16,549	21,514	25,816
Operating EBITDA (Rsm)	1,819	1,528	2,241	3,933	5,360
Net Profit (Rsm)	654	604	978	2,364	3,418
Core EPS (Rs)	5.3	4.2	6.2	15.1	21.8
Core EPS Growth	113.6%	(19.2%)	46.8%	141.7%	44.6%
FD Core P/E (x)	19.80	24.51	16.70	6.91	4.78
DPS (Rs)	0.3	0.3	0.5	1.2	1.7
Dividend Yield	0.41%	0.37%	0.60%	1.45%	2.09%
EV/EBITDA (x)	9.43	12.94	9.82	5.29	3.61
P/FCFE (x)	1,166.19	(40.60)	(15.63)	20.39	8.93
Net Gearing	49.3%	62.8%	49.0%	28.1%	13.5%
P/BV (x)	2.06	2.18	1.73	1.27	0.99
ROE	12.5%	8.7%	11.5%	21.2%	23.3%
% Change In Core EPS Estimates					
InCred Research/Consensus EPS (x)					

SOURCES: INCRED RESEARCH, COMPANY REPORTS

1200


900

600

300

0

#### **BY THE NUMBERS**



## Profit & Loss

Chemicals - Overall | India

Camlin Fine Sciences | September 04, 2024

(Rs mn)	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
Total Net Revenues	11,871	14,121	16,549	21,514	25,816
Gross Profit	6,036	6,526	8,936	12,048	14,457
Operating EBITDA	1,819	1,528	2,241	3,933	5,360
Depreciation And Amortisation	(443)	(560)	(633)	(698)	(715)
Operating EBIT	1,376	968	1,608	3,235	4,645
Financial Income/(Expense)	(375)	(358)	(600)	(375)	(375)
Pretax Income/(Loss) from Assoc.		(1)			
Non-Operating Income/(Expense)	50	330	300	300	300
Profit Before Tax (pre-El)	1,051	940	1,308	3,160	4,569
Exceptional Items					
Pre-tax Profit	1,051	940	1,308	3,160	4,569
Taxation	(397)	(336)	(330)	(796)	(1,151)
Exceptional Income - post-tax					
Profit After Tax	654	604	978	2,364	3,418
Minority Interests					
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	654	604	978	2,364	3,418
Recurring Net Profit	654	604	978	2,364	3,418
Fully Diluted Recurring Net Profit	654	604	978	2,364	3,418

Cash Flow					
(Rs mn)	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
EBITDA	1,819	1,528	2,241	3,933	5,360
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(659)	64	(3,056)	(2,661)	(2,705)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense	324	(126)	300	300	300
Other Operating Cashflow	425	650	600	600	600
Net Interest (Paid)/Received	(375)	(358)	(600)	(375)	(375)
Tax Paid	(359)	(304)	(330)	(796)	(1,151)
Cashflow From Operations	1,174	1,454	(845)	1,001	2,028
Сарех	(839)	(2,138)	(200)	(200)	(200)
Disposals Of FAs/subsidiaries	1				
Acq. Of Subsidiaries/investments					
Other Investing Cashflow	(490)	(353)			
Cash Flow From Investing	(1,329)	(2,491)	(200)	(200)	(200)
Debt Raised/(repaid)	166	672			
Proceeds From Issue Of Shares	299	948			
Shares Repurchased					
Dividends Paid	(54)	(7)	(98)	(236)	(342)
Preferred Dividends					
Other Financing Cashflow	(25)	(254)			
Cash Flow From Financing	386	1,360	(98)	(236)	(342)
Total Cash Generated	232	323	(1,143)	564	1,486
Free Cashflow To Equity	11	(364)	(1,045)	801	1,828
Free Cashflow To Firm	221	(679)	(445)	1,176	2,203

SOURCES: INCRED RESEARCH, COMPANY REPORTS

### Chemicals - Overall ∣ India Camlin Fine Sciences ∣ September 04, 2024

## BY THE NUMBERS...cont'd

(Rs mn)	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
Total Cash And Equivalents	1,383	1,421	924	1,108	2,584
Total Debtors	2,707	2,997	3,774	4,906	5,887
Inventories	3,200	3,709	4,461	5,799	6,959
Total Other Current Assets	656	809	1,964	2,817	3,955
Total Current Assets	7,947	8,935	11,123	14,630	19,385
Fixed Assets	5,369	7,406	6,848	6,350	5,835
Total Investments	94	72	94	94	94
Intangible Assets	684	757	684	684	684
Total Other Non-Current Assets	722	831	722	722	722
Total Non-current Assets	6,869	9,065	8,349	7,851	7,336
Short-term Debt	2,169	2,349	2,169	2,169	2,169
Current Portion of Long-Term Debt			· · · · · · · · · · · · · · · · · · ·		
Total Creditors	1,584	2,338	2,208	2,871	3,445
Other Current Liabilities	1,023	1,265	1,023	1,023	1,023
Total Current Liabilities	4,776	5,953	5,401	6,063	6,637
Total Long-term Debt	2,732	3,876	3,732	2,732	2,732
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	84	385	84	84	84
Total Non-current Liabilities	2,817	4,261	3,816	2,817	2,817
Total Provisions	91	136	91	91	91
Total Liabilities	7,684	10,350	9,308	8,971	9,545
Shareholders Equity	6,434	7,479	9,467	12,812	16,478
Minority Interests	697	171	697	697	697
Total Equity	7,132	7,651	10,164	13,509	17,175
Key Ratios					
Key Ratios					
	Mar-21A	Mar-22A	Mar-23F	Mar-24F	Mar-25F
Revenue Growth	13.1%	19.0%	17.2%	30.0%	20.0%
Operating EBITDA Growth	39.2%	(16.0%)	46.6%	75.5%	36.3%
Operating EBITDA Margin	15.3%	10.8%	13.5%	18.3%	20.8%
Net Cash Per Share (Rs)	(27.59)	(30.61)	(31.70)	(24.17)	(14.76)
BVPS (Rs)	50.46	47.65	60.30	81.61	104.97
Gross Interest Cover	3.67	2.71	2.68	8.62	12.38
Effective Tax Rate	37.8%	35.8%	25.2%	25.2%	25.2%
Net Dividend Payout Ratio	8.3%	10.0%	10.0%	10.0%	10.0%
Accounts Receivables Days	80.48	73.72	74.67	73.63	76.30
Inventory Days	193.34	166.01	195.85	197.81	204.98
Accounts Payables Days	103.88	94.24	108.98	97.92	101.46
ROIC (%)	9.6%	5.8%	9.3%	15.9%	20.0%
ROCE (%)	12.7%	7.4%	10.7%	18.7%	22.9%
Return On Average Assets	6.5%	5.1%	7.6%	12.6%	15.0%

SOURCES: INCRED RESEARCH, COMPANY REPORTS

#### DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd. (formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. While every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which is believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made (information barriers and other arrangements may be established, where necessary, to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short-term views, etc.) that are inconsistent with and reach a different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

Research Analyst or his/her relative(s) or InCred Research Services Private Limited or our associate may have any financial interest in the subject company.

Research Analyst or his/her relatives or InCred Research Services Limited or our associates may have actual or beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the Research Report.

Research Analyst or his/her relative or InCred Research Services Private Limited or our associate entities may have any other material conflict of interest at the time of publication of the Research Report.

In the past 12 months, IRSPL or any of its associates may have:

- a) Received any compensation/other benefits from the subject company,
- b) Managed or co-managed public offering of securities for the subject company,
- c) Received compensation for investment banking or merchant banking or brokerage services from the subject company,
- d) Received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company

We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.

Research Analyst may have served as director, officer, or employee in the subject company.

We or our research analyst may engage in market-making activity of the subject company.

#### Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his
  or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and
  autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based on any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in this report and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.

Recommendation	Framework
Stock Ratings	Definition:
Add	The stock's total return is expected to exceed 10% over the next 12 months.
Hold	The stock's total return is expected to be between 0% and positive 10% over the next 12 months.
Reduce	The stock's total return is expected to fall below 0% or more over the next 12 months.
	eturn of a stock is defined as the sum of the: (i) percentage difference between the target price and the current price and (ii) the forward net e stock. Stock price targets have an investment horizon of 12 months.
Sector Ratings	Definition:
Overweight	An Overweight rating means stocks in the sector have, on a market cap-weighted basis, a positive absolute recommendation.
Neutral	A Neutral rating means stocks in the sector have, on a market cap-weighted basis, a neutral absolute recommendation.
Underweight	An Underweight rating means stocks in the sector have, on a market cap-weighted basis, a negative absolute recommendation.
Country Ratings	Definition:
Overweight	An Overweight rating means investors should be positioned with an above-market weight in this country relative to benchmark.
Neutral	A Neutral rating means investors should be positioned with a neutral weight in this country relative to benchmark.
Underweight	An Underweight rating means investors should be positioned with a below-market weight in this country relative to benchmark.